文献速递系统性红斑狼疮

甲泼尼龙冲击治疗与系统性红斑狼疮持续缓解:纵向Lupus-Cruces-Bordeaux起始队列的倾向评分分析

Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2024-05-02

该观察性研究纳入233例系统性红斑狼疮(SLE)患者,分析诊断后第一年内使用甲泼尼龙冲击(MP)对持续缓解的影响。MP还降低中度与重度活动患者第一年泼尼松平均用量。

要点

  • 中度活动患者校正OR 5.28(95%CI 1.27-21.97,P=0.022),中重度活动校正OR 4.07(95%CI 1.11-14.82,P=0.033)。
  • MP降低第一年泼尼松平均用量:中度活动6.6 vs 10.2 mg/天(P=0.017),重度活动14 vs 28 mg/天(P=0.015)。

核心结论

  • 本研究支持使用MP诱导SLE患者持续缓解,尤其在中度和重度活动患者中。
  • 长期使用羟氯喹(HCQ)也有助于实现持续缓解。

研究设计与样本

  • 研究为观察性研究,数据来自Lupus-Cruces-Bordeaux队列的常规临床诊疗记录。
  • 共纳入233例患者,终点为持续缓解(即连续五年年度访视期间均缓解)。
  • 采用倾向评分及包含其他治疗协变量的逻辑回归进行校正。

主要发现

  • 132例患者(57%)实现持续缓解。
  • 中度活动患者校正OR 5.28(95%CI 1.27-21.97,P=0.022);中重度活动患者校正OR 4.07(95%CI 1.11-14.82,P=0.033)。
  • MP降低第一年泼尼松平均用量:中度活动患者平均6.6 vs 10.2 mg/天(P=0.017);重度活动患者平均14 vs 28 mg/天(P=0.015)。
  • HCQ使用时间越长,持续缓解的 odds 越高;初始泼尼松剂量越高,持续缓解的 odds 越低。

关键数值与推荐

  • 基线SLEDAI-2K评分<6、6-12、>12分别反映轻度、中度、重度活动。
  • 持续缓解定义为连续五年年度访视期间均处于缓解。

临床怎么用

  • 原文结论支持使用MP诱导SLE患者持续缓解,尤其在中度和重度活动患者中。
  • 原文结论指出长期使用HCQ也有助于实现持续缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to analyze the effect of methylprednisolone pulses (MP), given during the first year after the diagnosis of systemic lupus erythematosus (SLE), in achieving prolonged remission according to the degree of lupus activity at presentation. METHODS: We conducted an observational study of routine clinical care data from the Lupus-Cruces-Bordeaux cohort. The end point was prolonged remission (ie, during five consecutive yearly visits). The effect of MP on remission during the first year was analyzed in the whole cohort and according to the baseline Systemic Lupus Erythematosus Disease Activity Index 2000 score: <6, 6 to 12, and >12, reflecting mild, moderate, and severe activity, respectively. For adjustment, logistic regression with propensity score (PS) and other therapeutic covariates was performed. RESULTS: Two hundred thirty-three patients were included. Prolonged remission was achieved by 132 patients (57%). MP were associated with prolonged remission (PS-adjusted odds ratio [OR] 2.50, 95% confidence interval [CI] 1.04-623, P = 0.042). A strong clinical effect was seen among patients with moderate (adjusted OR 5.28, 95% CI 1.27-21.97, P = 0.022) and moderate-severe SLE activity (adjusted OR 4.07, 95% CI 1.11-14.82, P = 0.033). The administration of MP resulted in reduced average dosages of prednisone during the first year among patient with moderate (mean 6.6 vs 10.2 mg/day, P = 0.017) and severe activity (mean 14 vs 28 mg/day, P = 0.015). The odds of prolonged remission were increased by longer-term use of hydroxychloroquine (HCQ) and decreased by higher initial doses of prednisone. CONCLUSION: This study supports the use of MP to induce prolonged remission in patients with SLE, particularly in those with moderate and severe activity. The extended use of HCQ also contributes to achieve prolonged remission.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Ruiz-Irastorza G, Paredes-Ruiz D, Herrero-Galvan M, et al. Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort. Arthritis Care Res (Hoboken). 2024. PMID: 38529678. doi:10.1002/acr.25334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。